Cabozantinib in patients with platinum-refractory metastatic urothelial carcinoma: an open-label, single-centre, phase 2 trial.
Adult
Aged
Anilides
/ therapeutic use
Antineoplastic Agents
/ therapeutic use
Carcinoma, Transitional Cell
/ drug therapy
Drug Resistance, Neoplasm
/ drug effects
Female
Humans
Male
Middle Aged
Platinum Compounds
/ therapeutic use
Protein Kinase Inhibitors
/ therapeutic use
Pyridines
/ therapeutic use
Urologic Neoplasms
/ drug therapy
Journal
The Lancet. Oncology
ISSN: 1474-5488
Titre abrégé: Lancet Oncol
Pays: England
ID NLM: 100957246
Informations de publication
Date de publication:
08 2020
08 2020
Historique:
received:
03
01
2020
revised:
12
03
2020
accepted:
19
03
2020
pubmed:
10
7
2020
medline:
22
8
2020
entrez:
10
7
2020
Statut:
ppublish
Résumé
Cabozantinib is a multikinase inhibitor of MET, VEGFR, AXL, and RET, which also has an effect on the tumour immune microenvironment by decreasing regulatory T cells and myeloid-derived suppressor cells. In this study, we examined the activity of cabozantinib in patients with metastatic platinum-refractory urothelial carcinoma. This study was an open-label, single-arm, three-cohort phase 2 trial done at the National Cancer Institute (Bethesda, MD, USA). Eligible patients were 18 years or older, had histologically confirmed urothelial carcinoma or rare genitourinary tract histologies, Karnofsky performance scale index of 60% or higher, and documented disease progression after at least one previous line of platinum-based chemotherapy (platinum-refractory). Cohort one included patients with metastatic urothelial carcinoma with measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Two additional cohorts that enrolled in parallel (patients with bone-only urothelial carcinoma metastases and patients with rare histologies of the genitourinary tract) were exploratory. Patients received cabozantinib 60 mg orally once daily in 28-day cycles until disease progression or unacceptable toxicity. The primary endpoint was investigator-assessed objective response rate by RECIST in cohort one. Response was assessed in all patients who met the eligibility criteria and who received at least 8 weeks of therapy. All patients who received at least one dose of cabozantinib were included in the safety analysis. This completed study is registered with ClinicalTrials.gov, NCT01688999. Between Sept 28, 2012, and Oct, 20, 2015, 68 patients were enrolled on the study (49 in cohort one, six in cohort two, and 13 in cohort three). All patients received at least one dose of cabozantinib. The median follow-up was 61·2 months (IQR 53·8-70·0) for the 57 patients evaluable for response. In the 42 evaluable patients in cohort one, there was one complete response and seven partial responses (objective response rate 19%, 95% CI 9-34). The most common grade 3-4 adverse events were fatigue (six [9%] patients), hypertension (five [7%]), proteinuria (four [6%]), and hypophosphataemia (four [6%]). There were no treatment-related deaths. Cabozantinib has single-agent clinical activity in patients with heavily pretreated, platinum-refractory metastatic urothelial carcinoma with measurable disease and bone metastases and is generally well tolerated. Cabozantinib has innate and adaptive immunomodulatory properties providing a rationale for combining cabozantinib with immunotherapeutic strategies. National Cancer Institute Intramural Program and the Cancer Therapy Evaluation Program.
Sections du résumé
BACKGROUND
Cabozantinib is a multikinase inhibitor of MET, VEGFR, AXL, and RET, which also has an effect on the tumour immune microenvironment by decreasing regulatory T cells and myeloid-derived suppressor cells. In this study, we examined the activity of cabozantinib in patients with metastatic platinum-refractory urothelial carcinoma.
METHODS
This study was an open-label, single-arm, three-cohort phase 2 trial done at the National Cancer Institute (Bethesda, MD, USA). Eligible patients were 18 years or older, had histologically confirmed urothelial carcinoma or rare genitourinary tract histologies, Karnofsky performance scale index of 60% or higher, and documented disease progression after at least one previous line of platinum-based chemotherapy (platinum-refractory). Cohort one included patients with metastatic urothelial carcinoma with measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Two additional cohorts that enrolled in parallel (patients with bone-only urothelial carcinoma metastases and patients with rare histologies of the genitourinary tract) were exploratory. Patients received cabozantinib 60 mg orally once daily in 28-day cycles until disease progression or unacceptable toxicity. The primary endpoint was investigator-assessed objective response rate by RECIST in cohort one. Response was assessed in all patients who met the eligibility criteria and who received at least 8 weeks of therapy. All patients who received at least one dose of cabozantinib were included in the safety analysis. This completed study is registered with ClinicalTrials.gov, NCT01688999.
FINDINGS
Between Sept 28, 2012, and Oct, 20, 2015, 68 patients were enrolled on the study (49 in cohort one, six in cohort two, and 13 in cohort three). All patients received at least one dose of cabozantinib. The median follow-up was 61·2 months (IQR 53·8-70·0) for the 57 patients evaluable for response. In the 42 evaluable patients in cohort one, there was one complete response and seven partial responses (objective response rate 19%, 95% CI 9-34). The most common grade 3-4 adverse events were fatigue (six [9%] patients), hypertension (five [7%]), proteinuria (four [6%]), and hypophosphataemia (four [6%]). There were no treatment-related deaths.
INTERPRETATION
Cabozantinib has single-agent clinical activity in patients with heavily pretreated, platinum-refractory metastatic urothelial carcinoma with measurable disease and bone metastases and is generally well tolerated. Cabozantinib has innate and adaptive immunomodulatory properties providing a rationale for combining cabozantinib with immunotherapeutic strategies.
FUNDING
National Cancer Institute Intramural Program and the Cancer Therapy Evaluation Program.
Identifiants
pubmed: 32645282
pii: S1470-2045(20)30202-3
doi: 10.1016/S1470-2045(20)30202-3
pmc: PMC8236112
mid: NIHMS1615704
pii:
doi:
Substances chimiques
Anilides
0
Antineoplastic Agents
0
Platinum Compounds
0
Protein Kinase Inhibitors
0
Pyridines
0
cabozantinib
1C39JW444G
Banques de données
ClinicalTrials.gov
['NCT01688999']
Types de publication
Clinical Trial, Phase II
Journal Article
Research Support, N.I.H., Extramural
Research Support, N.I.H., Intramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
1099-1109Subventions
Organisme : Intramural NIH HHS
ID : ZIA BC010666
Pays : United States
Organisme : Intramural NIH HHS
ID : ZIA BC011594
Pays : United States
Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2020 Elsevier Ltd. All rights reserved.
Références
Clin Genitourin Cancer. 2017 Feb;15(1):77-85
pubmed: 27328856
Lancet. 2016 May 7;387(10031):1909-20
pubmed: 26952546
Clin Genitourin Cancer. 2013 Jun;11(2):175-81
pubmed: 23228446
J Clin Oncol. 2010 Apr 10;28(11):1850-5
pubmed: 20231682
J Nucl Med. 2016 Dec;57(12):1872-1879
pubmed: 27445292
J Natl Cancer Inst. 2014 Apr;106(4):dju033
pubmed: 24634505
Oncologist. 2017 Jan;22(1):25-32
pubmed: 27789775
J Clin Oncol. 2012 Jan 10;30(2):191-9
pubmed: 22162575
J Leukoc Biol. 2014 Aug;96(2):295-303
pubmed: 24714552
J Clin Oncol. 2005 Jul 20;23(21):4602-8
pubmed: 16034041
Lancet. 2017 Jan 7;389(10064):67-76
pubmed: 27939400
N Engl J Med. 2017 Mar 16;376(11):1015-1026
pubmed: 28212060
Anticancer Drugs. 2013 Apr;24(4):422-5
pubmed: 23407060
J Clin Oncol. 2019 Oct 10;37(29):2592-2600
pubmed: 31356140
N Engl J Med. 2004 Aug 19;351(8):781-91
pubmed: 15317891
Thyroid. 2014 Aug;24(8):1223-31
pubmed: 24724719
Science. 2015 Nov 20;350(6263):985-90
pubmed: 26494174
Eur J Radiol. 2015 Sep;84(9):1708-14
pubmed: 26149529
N Engl J Med. 2015 Nov 5;373(19):1814-23
pubmed: 26406150
Lancet Oncol. 2017 Mar;18(3):312-322
pubmed: 28131785
J Clin Oncol. 2017 Feb 20;35(6):591-597
pubmed: 28199818
N Engl J Med. 2018 Jul 05;379(1):54-63
pubmed: 29972759
J Clin Oncol. 2013 Oct 10;31(29):3639-46
pubmed: 24002501
Clin Cancer Res. 2006 Jul 15;12(14 Pt 1):4154-62
pubmed: 16857786
Lancet Oncol. 2017 Nov;18(11):1483-1492
pubmed: 28967485
JAMA Dermatol. 2015 Feb;151(2):170-7
pubmed: 25427282
BJU Int. 2014 Mar;113(3):429-36
pubmed: 24053564
Bone. 2015 Dec;81:581-592
pubmed: 26279137
Nat Rev Clin Oncol. 2019 Jun;16(6):356-371
pubmed: 30705439
Eur J Nucl Med Mol Imaging. 2020 Jan;47(1):178-184
pubmed: 31522271
J Clin Oncol. 2017 Jul 1;35(19):2117-2124
pubmed: 28375787
J Clin Oncol. 2013 Feb 20;31(6):724-30
pubmed: 23341513